PSMA-Targeting Dual-Target Radiopharmaceuticals for Prostate Cancer Imaging
Key facts
- Who runs it
- The First Affiliated Hospital of Soochow University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Early phase 1
- People taking part
- 30 people, planned
- Started
- 24 Sept 2026
- Expected to end
- 24 Sept 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- 68Ga-Labeled EphA2/PSMA Dual-Target Radiotracer PET/CT imaging
- 68Ga-Labeled ACP3/PSMA Dual-Target Radiotracer PET/CT imaging
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Voluntary provision of written informed consent; Male, aged 18-80 years; Pathologically confirmed prostate cancer, including newly diagnosed disease, recurrence after surgery, or metastatic disease; At least one measurable or evaluable lesion; Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; Hematological parameters, liver and kidney function, and electrolyte levels meeting protocol-defined requirements; Ability to cooperate with and complete PET/CT imaging
Who cannot take part
- Inability to tolerate or cooperate with PET/CT imaging, for example, due to claustrophobia; Severe, uncontrolled disease affecting vital organs, including the heart, liver, or kidneys; Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will evaluate the diagnostic performance and safety of gallium-68 (68Ga)-labeled dual-target imaging agents in patients with prostate cancer. These investigational agents are designed to target either EphA2 and prostate-specific membrane antigen (PSMA), or ACP3 and PSMA, for positron emission tomography/computed tomography (PET/CT) imaging.
Read full original descriptionShow less
The main aims are to assess how well these imaging agents detect prostate cancer lesions, evaluate their safety, and estimate the radiation doses received by different organs and the body as a whole. The study will also explore their potential use in early diagnosis, determining the extent of cancer spread, and detecting cancer recurrence.
The 2 groups in the trial
- 68Ga-Labeled EphA2/PSMA Dual-Target PET/CT ImagingTreatment being tested
Patients with prostate cancer will receive an intravenous injection of a 68Ga-labeled EphA2/PSMA dual-target radiotracer and undergo PET/CT imaging. Diagnostic performance, safety, biodistribution, and radiation dosimetry will be evaluated. Imaging findings will be compared with \[18F\]FDG PET/CT or single-target PSMA PET/CT findings according to the study protocol.
Treatment: 68Ga-Labeled EphA2/PSMA Dual-Target Radiotracer PET/CT imaging
- 68Ga-Labeled ACP3/PSMA Dual-Target PET/CT ImagingTreatment being tested
Patients with prostate cancer will receive an intravenous injection of a 68Ga-labeled ACP3/PSMA dual-target radiotracer and undergo PET/CT imaging. Diagnostic performance, safety, biodistribution, and radiation dosimetry will be evaluated. Imaging findings will be compared with \[18F\]FDG PET/CT or single-target PSMA PET/CT findings according to the study protocol.
Treatment: 68Ga-Labeled ACP3/PSMA Dual-Target Radiotracer PET/CT imaging
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Clinical Study Evaluating the Diagnostic Performance and Safety of PSMA-Targeting Dual-Target Radiopharmaceuticals in Patients With Prostate Cancer
- Record updated
- 12 November 2026